You have probably seen the ads online. A tiny vial, a thin needle, promises of faster recovery or leaner muscle. Peptide injections have moved from gyms and bodybuilding forums into mainstream wellness clinics.
The Department of Health and Human Services (HHS) submitted a plan to the White House budget office on Thursday, October 15.
The policy would let specialty pharmacies prepare several unapproved peptide injections for patients with a prescription, according to the Associated Press.
The plan would not formally approve the drugs. It uses a legal workaround called enforcement discretion. The FDA would agree not to act against compounding pharmacies that prepare the peptides on an approved list.
Also read: Scientists reveal how much whole grain you need to eat for a healthier heart
Compounding pharmacies mix custom drugs on request. The FDA added BPC-157, one of the most popular peptides in wellness circles, to its restricted list for pharmacy compounding in 2023.
Behind the push is Health Secretary Robert F. Kennedy Jr. Before taking office he said FDA's war on peptides would end. Easier access to peptides is part of his MAHA agenda.
What peptides actually are
Peptides are short chains of amino acids, the building blocks of proteins. The body uses them to trigger hormones that drive growth, metabolism and tissue repair.
Some peptides are already approved medicines. Semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is a peptide. So is insulin.
Also read: Massive study of 1 million women reveals how menopause changes the body in an instant
But the compounds at the center of the new policy, including BPC-157 and TB-500, are different. They have never been through the full FDA approval process.
BPC-157 is sold online for muscle growth and injury recovery. Almost all the published research comes from a single group of scientists in Croatia, and nearly all the data is from rodents, according to STAT News.
What FDA scientists are warning about
The FDA has flagged BPC-157 and more than a dozen other injectable peptides as too risky for pharmacy compounding. The agency has cited contamination, allergic reactions and the possibility that the drugs could help tumors grow new blood vessels.
Those warnings have not changed inside the agency. In July 2026, an outside panel of FDA advisers reviewed seven peptides, and FDA staff scientists concluded that none had been studied enough to establish their safety or effectiveness.
Also read: Podiatrists warn: You should never wear these shoes at home
The panel still voted narrowly to recommend dropping the restrictions on six of the seven peptides, over the objections of agency staff.
Matthew Fedoruk, chief science officer at the U.S. Anti-Doping Agency, has warned that gray-market vials sold as peptides often contain something else entirely. Buyers may end up with a steroid, or even plain water, because the products carry no quality controls.
What this could mean for consumers
If the White House clears the policy, telehealth companies and wellness clinics are expected to start offering the shots quickly. Hims & Hers and Noom have already signaled plans to add peptides when restrictions ease.
Wall Street analysts put the market opportunity at 2 to 3 billion dollars.
Also read: New research links frequent afternoon naps to dementia risk
For now, the plan is still under review at the Office of Management and Budget. The FDA has not published a final policy or spelled out exactly which peptides will qualify.
Anyone considering a peptide injection should talk with their own doctor first, especially people with a history of cancer or autoimmune disease.
Also read: This is what eating salmon twice a week does to your heart and cholesterol
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.